- NCIt
- C4925
Loading cancer entity…
Loading cancer entity…
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 210 | Duboce Biopharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04715191 |
| Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors |
| recruiting |
| Phase 1 |
| 24 |
| Baylor College of MedicineOTHER |
| 1 |
| Aug 6, 2026 |
| clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT07218913 | Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors | recruiting | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials